ARTICLE | Company News
Helsinn, Roche Netupitant deal
June 2, 2005 1:18 AM UTC
Roche (SWX:ROCZ) granted Helsinn (Lugano, Switzerland) an exclusive license to Netupitant, a neurokinin-1 (NK-1) (Substance P) receptor antagonist, to prevent chemotherapy-induced nausea and vomiting ...